EP1984004A2 - Therapy-enhancing glucan - Google Patents
Therapy-enhancing glucanInfo
- Publication number
- EP1984004A2 EP1984004A2 EP07718218A EP07718218A EP1984004A2 EP 1984004 A2 EP1984004 A2 EP 1984004A2 EP 07718218 A EP07718218 A EP 07718218A EP 07718218 A EP07718218 A EP 07718218A EP 1984004 A2 EP1984004 A2 EP 1984004A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- glucan
- antibody
- subject
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001503 Glucan Polymers 0.000 title claims abstract description 68
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 73
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 46
- 201000011510 cancer Diseases 0.000 claims abstract description 41
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 23
- 238000009566 cancer vaccine Methods 0.000 claims abstract description 16
- 229940022399 cancer vaccine Drugs 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000003213 activating effect Effects 0.000 claims description 12
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 238000011285 therapeutic regimen Methods 0.000 claims description 10
- 230000001093 anti-cancer Effects 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- 230000002476 tumorcidal effect Effects 0.000 claims description 8
- 230000005975 antitumor immune response Effects 0.000 claims description 7
- 230000037452 priming Effects 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 150000002270 gangliosides Chemical class 0.000 claims description 6
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 102000001301 EGF receptor Human genes 0.000 claims description 5
- 108060006698 EGF receptor Proteins 0.000 claims description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 229920002498 Beta-glucan Polymers 0.000 abstract description 70
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract description 44
- 238000011282 treatment Methods 0.000 abstract description 23
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 241000124008 Mammalia Species 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 41
- 210000004881 tumor cell Anatomy 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000209219 Hordeum Species 0.000 description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 229960004641 rituximab Drugs 0.000 description 5
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 4
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229920002305 Schizophyllan Polymers 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 230000002434 immunopotentiative effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 208000037821 progressive disease Diseases 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920001491 Lentinan Polymers 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 108010059297 beta-glucan receptor Proteins 0.000 description 3
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229940115286 lentinan Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007236 host immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012325 curative resection Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000029565 malignant colon neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Definitions
- Glucans are a heterogeneous group of glucose polymers found in the cell walls of plants, bacteria and fungi.
- the basic structure of branched glucan consists of a linear backbone of ⁇ -l,3-linked glucose with ⁇ -1, 6-linked side branches of ⁇ -l,3-glu ⁇ an, ⁇ -l,3-glucan is the component responsible for the majority of biological activities of zymosan, a commonly used leukocyte stimulant derived from the cell wall of Bakers yeast (Saccharomyces cerevisiae) .
- Beta-glucans have been tested for tumor therapy in mice for nearly 40 years 1 ' 2 .
- Several forms of mushroom- derived beta-glucans are used clinically to treat cancer in Japan, including PSK (from Coriolus versicolor) , Lentinan and Schizophyllan.
- PSK has moderately improved survival rates in some cancer trials after gastrectomy 3 ' 4 , colorectal surgery 5 ' 5 , and esophagectomy 7 to remove primary tumors. Results have i>een less encouraging in breast cancer 8 ' 9 and leukemia 10 .
- Schizophyllan also moderately improved survival of patients with operable gastric cancer 11 , inoperable gastric cancer 12 ' 13 , and cervical cancer 14 .
- beta-glucans are not widely used by Western oncologists, beta-glucan containing botanical medicines such as Reishi and maitake 15 are widely used by U.S. cancer patients as alternative/complementary cancer therapies.
- beta-glucans especially from Bakers' yeast have long been employed as feed additives for animals, as dietary supplement for humans 17 , in treatment of wounds 18 , and as an active ingredient in skin cream formulations.
- the basic structural unit in beta-glucans is the ⁇ (l-»3) -linked glucosyl units.
- beta-glucans have various degrees of branching and of linkages in the side chains. The frequency and hinge-structure of side chains determine its immunomodulatory effect.
- Beta-glucans of fungal and yeast origin are normally insoluble in water, but can be made soluble either by acid hydrolysis or by derivatization introducing charged groups like -phosphate, -sulphate, amine, -carboxymethyl and so forth to the molecule 19"20 .
- This invention provides a composition comprising an effective amount of yeast beta-glucan capable of enhancing immune responses in a subject or a host.
- the enhanced immune responses are antitumor immune responses, which can be induced or initiated by various techniques or procedures generally known in the art.
- antitumor immune responses can be induced by antitumor antibodies, cancer vaccines, or other compositions intended to induce immune responses against cancer.
- the present invention provides a yeast beta-glucan composition capable of enhancing the efficacy of antitumor antibodies and/or their derivatives.
- the present invention provides a yeast beta-glucan composition capable of enhancing the efficacy of cancer vaccines, or the efficacy of other compositions intended to induce immune responses against cancer.
- Antibodies as used herein refer to any part of immunoglobulin molecules (e.g. a monoclonal antibody) having specific cancer cell binding affinity by which they are able to exercise anti-tumor activity. Examples are antigen binding fragments or derivatives of antibodies.
- the antibody used in the present invention can be a single monoclonal antibody or a combination of antibodies .
- the antibodies may be directed to at least one epitope or multiple epitopes of an antigen or multiple antigens. Accordingly, this invention encompasses at least one antibody.
- the cancer recognized by antibodies includes, but not limited to, neuroblastoma, melanoma, non-Hodgkin 1 s lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer colon cancer, liver cancer, stomach cancer, and other gastrointestinal cancers.
- This invention further provides the above compositions and a pharmaceutically acceptable carrier, thereby forming pharmaceutical compositions.
- This invention also provides a method for treating a subject with cancer, comprising administrating the above- described composition to the subject.
- the present invention provides a method for enhancing tumoricidal activities of antitumor antibody in a subject having cancer.
- cancer include, but are not limited to, neuroblastoma, melanoma, non-Hodgkin' s lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer, colon cancer, liver cancer, stomach cancer, or other gastrointestinal cancers .
- the above method comprises the steps of (a) administering to the subject antitumor antibody that binds to cancer cells in the subject; and (b) administering orally to the subject a composition comprising an effective amount of yeast glucan, wherein the orally administered glucan enhances tumoricidal activities of the antibody.
- the antibody is a monoclonal antibody. More preferably, the antibody is capable of activating complement or activating antibody dependent cell-mediated cytotoxicity.
- Representative examples of antitumor antibodies include, but are not limited to, antibodies that recognize CD20, CD22, HER-2/neu, CD25, epidermal growth factor receptor, or gangliosides .
- the yeast glucan used in the above method has an average molecular weight of about 16,000 to about 17,000 daltons, with a range from about 6,000 to about 30,000 daltons, or from about 6,000 to about 25,000 daltons .
- the yeast glucan can be administered at the same or different time as the administration of the antitumor antibody.
- the yeast glucan is capable of priming or inducing secretion of cytokines, chemokines or growth factors by leukocytes .
- the present invention also provides a therapeutic regimen for a subject having cancer, the regimen comprising a cooperative anti-cancer effect resulting from administering to a subject in need thereof: (i) antitumor antibody that binds to cancer cells in the subject, or a cancer vaccine composition intended to induce antitumor immune responses; and (ii) an effective amount of yeast glucan which is administered to the subject orally, wherein the orally administered glucan enhances tumoricidal activities of the antibody or the cancer vaccine composition.
- the yeast glucan can be administered at the same or different time as the administration of the antitumor antibody or the cancer vaccine. Examples of antitumor antibodies and yeast glucan have been described above.
- cancer vaccine examples include whole tumor cells, tumor cell lysates, tumor cell derived RNAs, tumor cell derived proteins, tumor cell derived peptides, tumor cell derived carbohydrates, tumor cell derived lipids, tumor cell derived DNA sequences and gene modified tumor cells, either clinically synthesized or recombinant products to serve as tumor anti-genes.
- tumor cells could be derived from a patient's own tumor or tumor from an unrelated donor.
- the present invention also provides uses of an effective amount of yeast glucan for preparing an anti-cancer pharmaceutical composition.
- the glucan is administered to a subject orally to enhance tumoricidal activities in the subject.
- the anti-cancer pharmaceutical composition may further comprise antitumor antibodies that bind to cancer cells in the subject, or a cancer vaccine composition intended to induce antitumor immune responses.
- the yeast glucan can be administered to a subject at the same or different time as the administration of the antitumor antibody or the cancer vaccine . Representative examples of antitumor antibodies, cancer vaccine, and yeast glucan have been described above .
- Figure 1 shows treatment of disseminating human lymphoma in SCID mice using Rituxan and barley or yeast ⁇ - glucan.
- Five millions Daudi cells in 100 ⁇ l normal saline were injected intravenously (i.v.) into SCID mice. Tumors grew systemically and the mice became paralyzed when tumor cells infiltrated the spinal canal, resulting in hind-leg paralysis. The mice were sacrificed at the onset of paralysis or when the animals lost' 10% of their body weight. Therapy was initiated ten days after injection of tumor cells.
- rituximab Genentech, San Francisco, CA
- 400 ⁇ g glucan was administered orally via intragastric gavage daily for 29 days.
- the mice were weighed weekly and observed clinically at least once daily.
- Mice receiving rituxan plus barley glucan or rituxan plus yeast soluble glucan have a highly significant prolonged survival (p ⁇ 0.05) .
- FIG. 2 shows 1 H NMR spectrum of a typical SBG (Soluble Beta Glucan) sample (Biotec Pharamacon ASA, Troms ⁇ , Norway) .
- a SBG sample was dissolved in DMSO-d e at a concentration of approximately 20 mg/ml and with a few drops of TFA-d added.
- the spectrum (cut-out from 2.7 to 5.5 ppm) was collected over 2 hours on a JEOL ECX 400 NMR spectrometer at 80 0 C. Chemical shifts were referenced to residual proton resonance from the DMSO-d 6 at 2.5 ppm, and the spectrum was baseline corrected.
- Figure 3 shows viscosity profile of SBG. Profiles for a 2% solution of SBG at 20 or 30 0 C at different shear rates were shown. Glycerol (87%) was used as reference solution.
- Figure 4 shows beta-glucan comprising a beta-1,3- linked backbone.
- Figure 5 shows beta-1, 3-glucans isolated from yeast with beta-1, 3-linked side chains anchored to the main chain through beta-1, 6 -linkage .
- the meaning of the expression "higher order conformation” defines the formation of a molecule by transformation of a collection of free atoms, which find themselves in a random spatial configuration, into a more stable non-random pattern of those same atoms. In other words, these atoms have connected themselves to each other, resulting in a new molecule, a new totality.
- the connection in this case is chemical, i.e. by means of chemical bonds like hydrogen bonds .
- Several of such molecules can in turn react with each other, resulting in other molecules, either of the same size, or possibly of a larger size. Both are new totalities again.
- the larger molecules are higher-order totalities.
- the expression “immunostimulating” refers to stimulating the immune system by inducing activation or increasing activity of any components of the immune system.
- the expression “immunopotentiating” refers to the activities of one substance that enhance or increase the immunostimulating effects of another substance .
- beta-glucan to have immunopotentiating activity is likely the result of its ability to present multiple epitopes for interaction with receptors on the target cells, thereby clustering beta-glucan receptors and mimicking the challenge by a pathogenic organism. Such multiple interactions with specific receptors on the cell are believed to depend partly on glucan's ability to form "higher order" structures presenting multiple binding epitopes in close vicinity. Soluble beta-glucan formulations which possess durable interchain associations, as expressed by a high viscosity profile, would thus be likely candidates for expressing "immunpotentiating" abilities .
- cancer refers to pathological process that results in the formation and growth of a cancerous or malignant neoplasm.
- the term "effective amount” is used to describe that amount of a compound, when administered to an animal or a human, would lead to suppression or eradication of tumor growth or spread of the cancer, or other desirable immune responses.
- animal is used to describe an animal, preferably a mammal, more preferably a human, to whom treatment or method according to the present invention is provided.
- pharmaceutically acceptable carrier, additive or excipient means a chemical composition with which an appropriate glucan or derivative may be combined and which, following the combination, can be used to administer the appropriate glucan to treat animals, preferable mammals, and most preferably humans.
- beta-glucans of microbial origin like yeasts, are recognised by specific pattern recognition receptors on immune cells as a result of phylogenetic adaptation for detecting possible pathogens.
- Beta-glucans in e.g. fungal cell walls are major structural element that secure the strength and integrity of the cell and are thus vital for the organism.
- Beta-1, 3-glucans are present in almost all fungal cells and they are highly conserved 'structures, the latter being a prerequisite for the so-called Pathogen Associated Molecular Patterns (PAMPs) recognised by the immune system.
- PAMPs Pathogen Associated Molecular Patterns
- Immunologically active beta-glucans are likely to bind to beta-glucan receptor known as Dectin-1 when introduced to the organism through the gastrointestinal tract.
- beta-1, 3-glucans having the structural elements and conformations mimicking its fungal origin as being recognised by the immune cells would thus be considered favourable with respect to achieving an immune activation, especially when administered orally. It is likely that beta- 1, 3 and 1 , 4 glucans, although not derived from a microbial organism, would interact with the immune cells based on its similarity to conserved structures on pathogenic organisms . Examples of useful beta-glucans include, but are not limited to, particulate and soluble yeast cell wall glucans as described in PCT/IB95/00265 and EP 0759089.
- beta-1, 3- glucan compositions having the ability to form interchain associations, as exemplified in having a high viscosity profile as described for the barley beta-1, 3-1, 4-glucan preparations, would also be suitable candidates. Specific preparations of e.g. lentinan, scleroglucan and schizophyllan showing durable interchain interactions are likely to be effective.
- beta-1, 3-glucan formulations solublized by deriatization like glucan phosphates, glucan sulphates, carboxymethyl-glucans, and retaining the immunopotentialting activity of the native molecule and interchain assosiation would be possible active products.
- Beta-glucan formulations not presenting a pathogen- like feature could nevertheless be potent adjuvants for immunotherapy when administered directly into systemic distribution, like when given i.v. as described in Herlyn et al . (Monoclonal antibody-dependent murine macrophage-mediated cytotoxicity against human tumors is stimulated by lentinan. Jpn. J. Cancer Res. 16, 37-42 (1985)), or when given i.p. as described in U.S. Serial No ' . 60/261,911.
- the present invention discloses a composition for achieving a synergistic therapeutic effect in an animal, preferably a mammal, most preferably a human in need thereof, comprising (i) a viscous and immunopotentiating yeast beta-glucan composition comprising a beta-1, 3-linked backbone as shown in Figure 4 and (ii) an antitumor antibody, wherein the synergistic therapeutic effect is the eradication or suppression of cancer or tumor cells .
- the ability of yeast beta-glucans to have immunopotentiating activity is likely due to their ability to present multiple epitopes for interaction with receptors on the target cells, thereby clustering beta-glucan receptors and mimicking the challenge by a pathogenic organism.
- the beta-glucan composition comprises yeast beta-glucans with beta-l, 3-linked main chain having a molecular weight (MW) >6000 Da, and has side chains attached thereto giving a soluble product with strong interchain assosiations .
- Representative examples include, but are not limited to, beta-l, 3-glucans isolated from yeast with beta-l, 3-linked side chains anchored to the main chain through beta-l, 6-linkage (see Figure 5).
- Suitable forms of yeast glucans include, but are not limited to, particulate, soluble, or gel form.
- yeast beta-glucans is a mixture of soluble beta-glucan chains with molecular weight (MW) >6000 daltons that interact to give a higher order conformation which would exhibit immunostimulatory activity when administered orally to induce synergistic effect with the antibodies.
- the mixture of soluble beta-glucans comprise linear beta-1, 3- glucan chains with MW >6000 Da, or more preferably, with MW ranging from 6000-30,000 Da, together with branched high molecular weight beta-1, 3-glucan (MW >15,000 Da) with beta- 1,3 linked side chain (s) extending from within the main chain as shown in Figure 5.
- glucan As described above is SBG (Soluble Beta Glucan) produced by Biotec Pharamacon ASA
- Bakers' yeast is an underivatized aqueous soluble ⁇ -1, 3/1, 6- glucan characterized by NMR and chemical analysis to consist of polymers of ⁇ -l,3-linked D-glucose containing side chains of ⁇ -1, 3 and ⁇ -l,6-linked D-glucose (see Figure 2) .
- the yeast glucans have an average molecular weight of about 16,000 to about 17,000 daltons, with a range from about 6,000 to about 30,000 daltons, or from about 6,000 to about 25,000 daltons
- SBG shows a complex beta- glucan composition with high molecular weight chains having beta-1, 3-linked side chains attached to the repeating beta- 1,3-linked main chain through a beta-1, 6-linked branching point, and medium molecular weight linear beta-1, 3-glucan chains in the range of 6 - 15 kDa.
- SBG Soluble Beta Glucan
- SBG has been shown to be a potent immunostimulating agent for activating human leukocytes in vitro, e.g. priming and inducing the production of cytokines (see Engstad et al .
- yeast glucans of the present invention it is preferable for the yeast glucans of the present invention to have such functional properties of priming and inducing cytokine production by human leukocytes.
- Products having the desired structural features giving a higher order conformation like SBG that facilitates the needed interaction with responding cells in the intestinal tract would be the preferred products when administered orally.
- Their action as immunopotentiators in synergy with anti-cancer antibodies is likely to be at least as powerful when administered parenterally, e.g. when administered i.p., s.c, i.m. or i.v.
- Functional dose range of the glucans can be readily determined by one of ordinary skill in the art. For example, when administered orally the functional dose range would be in the area of 1-500 mg/kg b.w. (body weight) /day, more preferable 10-200 mg/kg b.w./day, or most preferable 20-80 mg/kg/day. In another embodiment, when administered parenterally the functional dose range would be 0.1-10 mg/kg b.w./day.
- dosages of the compound of the present invention administered to an animal will vary depending upon any number of factors, including but not limited to, the type of animal and type of cancer and disease state being treated, the age of the animal, the route of administration and the relative therapeutic index.
- Formulations suitable for oral administration of the beta-glucan include, but are not limited to, an aqueous or oily suspension, an aqueous or oily solution, or an emulsion. Such formulations can be administered by any means including, but not limited to, soft gelatin capsules.
- Liquid formulations of a pharmaceutical composition of the present invention which are suitable for oral administration may be prepared, packaged, and sold either in liquid form or in the form of a dry product intended for reconstitution with water or other suitable vehicle prior to use.
- the beta-glucan can be administered to an animal as frequently as several times daily, or it may be administered less frequently, such as once a day.
- the antibody treatment will for instance depend upon the type of antibody, the type of cancer, the severity of the cancer, and the condition of each patient.
- the beta-glucan treatment is closely interrelated with the antibody treatment regimen, and could be ahead of, concurrent with, or after the antibody administration.
- the frequency of the beta-glucan and antibody dose will be readily apparent to the skilled artisan and will depend upon any number of factors, such as, but not limited to, the type and severity of the disease being treated, and the type and age of the patients. Treatment with the substance of the present invention could happen at the same time or at different times. For example, the beta- glucan treatment could start a few days ahead of the i.v. antibody treatment, and then the beta-glucan is administered concurrently with the antibody. In another embodiment, beta- glucan treatment may continue for a few days after ending the antibody treatment.
- the antibody treatment could include a cocktail of antibodies or antibody-formulations/ modified antibodies and/or derivatives thereof .
- glucan When administered orally, glucan is taken up by macrophages and monocytes that carry these carbohydrates to the marrow and reticuloendothelial system from where they are released, in an appropriately processed form, onto myeloid cells including neutrophils and onto lymphoid cells including natural killer (NK) cells.
- the processed glucan binds to CR3 on these neutrophils and NK cells, and activating their antitumor cytotoxicity in the presence of tumor-specific antibodies .
- the present invention provides a composition comprising an effective amount of orally administered
- Glucans derived from cell walls of yeasts such as Saccharomyces cervisiae, may be used in the above-described compositions .
- glucans having ⁇ (l-3) and ⁇ (l-6) linkages such as SBG (Soluble Beta Glucan) produced by Biotec Pharamacon ASA (Troms ⁇ , Norway) , is used in the above-described compositions.
- SBG Soluble Beta Glucan
- the above mentioned pharmaceutical compositions may contain pharmaceutically acceptable carriers and other ingredients known to enhance and facilitate drug administration. The relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and condition of the subject treated.
- Such a pharmaceutical composition may comprise the active ingredient alone, in a form suitable for administration to a subject, or the pharmaceutical composition may comprise the active ingredient and one or more pharmaceutically acceptable carriers, one or more additional ingredients, or some combination of these.
- the active ingredient may be present in the pharmaceutical composition in forms which are generally well known in the art.
- compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology.
- preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single-or multi-dose unit.
- Controlled- or sustained-release formulations of a pharmaceutical composition of the present invention may be made using conventional technology.
- the above glucan composition may comprise a monoclonal antibody, or an antibody against cancer or tumor cells, which include but are not limited to anti-CEA antibody, anti-CD20 antibodies, anti-CD25 antibodies, anti- CD22 antibodies, anti-HER2 antibodies, anti-tenascin antibodies, MoAb M195, Dacluzimab, anti-TAG-72 antibodies, R24, Herceptin, Rituximab, 528, IgG, IgM, IgA, C225, Epratuzutnab, MoAb 3F8, and antibody directed at the epidermal growth factor receptor, or a ganglioside, such as GD3 or GD2.
- the antibody is a tumor-binding antibody.
- the antibody is capable of activating complement and/or activating antibody dependent cell-mediated cytotoxicity.
- the antibody modulates T-cell or B-cell function.
- the antibodies are effective against cancers which include neuroblastoma, melanoma, non-Hodgkin' s lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer, colon cancer, liver cancer, stomach cancer, or other gastrointestinal cancers.
- cancers which include neuroblastoma, melanoma, non-Hodgkin' s lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer, colon cancer, liver cancer, stomach cancer, or other gastrointestinal cancers.
- the present invention also provides a method for treating a subject comprising administrating the above- described composition to a subject.
- the present invention also provides a composition comprising an effective amount of orally administered (1- ⁇ 3) , (l->6) beta-glucan capable of enhancing the efficacy of vaccines.
- the " vaccine is against cancer or infectious agents, such as bacteria, viruses, fungi, or parasites .
- the present invention also provides a composition comprising an effective amount of orally administered (l->3) , (l->6) beta-glucan capable of enhancing host immunity.
- the host immunity includes, but is not limited to, antitumor immune responses.
- the present invention provides a composition comprising an effective amount of orally administered (l->3), (1- ⁇ 6) beta-glucan capable of enhancing the action of an agent in preventing tissue rejection.
- the tissue is transplanted tissue or transplanted organ or the host of graft-versus-host disease.
- kits for inhibiting cancer cell growth and/or metastasis includes a kit or an administration device comprising a glucan as described herein and information material which describes administering the glucan or a composition comprising the glucan to a human.
- the kit or administration device may have a compartment containing the glucan or the composition of the present invention.
- the "Information material” includes, but is not limited to, a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the invention for its designated use.
- the EL4 syngeneic mouse model of lymphoma was used to study antibody response to whole tumor vaccine in the presence of ⁇ -glucan.
- live EL4 tumor cells were planted subcutaneousIy or intravenously in immunocompetent C57B1/6 mice, they engrafted rapidly causing death from large tumor masses and metastases to distant organs.
- EL4 tumor cells were planted subcutaneousIy or intravenously in the presence of anti-GD2 antibody 3F8, tumor cell engraftment diminished.
- ⁇ -glucan is known to activate antigen-presenting cells
- EL4 cells were administered in the presence of 3F8 as a tumor vaccine to test if ⁇ -glucan can provide adjuvant effect to induce protective immunity.
- mice were vaccinated subcutaneously with EL4 lymphoma (as whole tumor vaccine) in the presence of anti-GD2 antibody 3F8 plus yeast ⁇ -glucan.
- Mouse sera were obtained at week 2, 4, and 8 after vaccination.
- Serum antibodies against surface antigens on EL4 cells were assayed by flow cytometry.
- Antibodies against total cell antigens were assayed by flow cytometry.
- Results from these experiments indicate that: (1) 3F8 was necessary to prevent subcutaneous EL4 tumor engraftment; (2) 3F8 enhanced antibody response to EL4 whole tumor vaccine; (3) live EL4 tumor vaccine stimulated a significantly higher immune response compared to irradiated EL4 tumor vaccine; (4) antibody titer against EL4 tumor increased with increasing dose of glucan as an adjuvant, with an optimal dose at 2 mg; and (5) the higher the dose of glucan, the longer the mice were protected when subsequently challenged with intravenous EL4 in a tumor prevention model.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic composition may further comprise antitumor antibodies or cancer vaccine composition, wherein the antitumor activitiesof the antitumor antibodies or the cancer vaccine composition are enhanced by the yeast glucan.
Description
THERAPY-ENHANCING YEAST GLUCAN
[0001] Thia application is a Continuation-In-Part of U.S. Application Wo. 11/334,763, filed January 17, 2006, which is hereby incorporated herein by reference.
[Q002] Throughout this application, various references are cited. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
Ϊ0003] Glucans are a heterogeneous group of glucose polymers found in the cell walls of plants, bacteria and fungi. The basic structure of branched glucan consists of a linear backbone of β-l,3-linked glucose with β-1, 6-linked side branches of β-l,3-gluσan, β-l,3-glucan is the component responsible for the majority of biological activities of zymosan, a commonly used leukocyte stimulant derived from the cell wall of Bakers yeast (Saccharomyces cerevisiae) .
[0004] Beta-glucans have been tested for tumor therapy in mice for nearly 40 years1'2. Several forms of mushroom- derived beta-glucans are used clinically to treat cancer in Japan, including PSK (from Coriolus versicolor) , Lentinan and Schizophyllan. In randomized trials in Japan, PSK has moderately improved survival rates in some cancer trials after gastrectomy3'4, colorectal surgery5'5, and esophagectomy7 to remove primary tumors. Results have i>een less encouraging in breast cancer8'9 and leukemia10. Schizophyllan also moderately improved survival of patients with operable gastric cancer11, inoperable gastric cancer12'13, and cervical
cancer14. While beta-glucans are not widely used by Western oncologists, beta-glucan containing botanical medicines such as Reishi and maitake15 are widely used by U.S. cancer patients as alternative/complementary cancer therapies.
[0005] In Europe and USA, beta-glucans especially from Bakers' yeast have long been employed as feed additives for animals, as dietary supplement for humans17, in treatment of wounds18, and as an active ingredient in skin cream formulations. The basic structural unit in beta-glucans is the β (l-»3) -linked glucosyl units. Depending upon the source and method of isolation, beta-glucans have various degrees of branching and of linkages in the side chains. The frequency and hinge-structure of side chains determine its immunomodulatory effect. Beta-glucans of fungal and yeast origin are normally insoluble in water, but can be made soluble either by acid hydrolysis or by derivatization introducing charged groups like -phosphate, -sulphate, amine, -carboxymethyl and so forth to the molecule19"20.
[0006. Previous studies that looked for a therapeutic effect of beta-glucan did not incorporate co-administration of therapeutic monoclonal antibodies (MoAb) as part of the protocol. When beta-glucan is administered without co- administration of MoAb, its tumor cytotoxic effect requires the presence of naturalIy-occurring antitumor antibodies which can be quite variable among patients and even in experimental mice. Thus, it is of interest to determine the therapeutic effects of co-administering beta-glucan and therapeutic monoclonal antibodies. It is also not clear whether therapeutic effect can be obtained by orally administered beta-glucan.
SUMMARY OP THE INVENTION
[0007] This invention provides a composition comprising an effective amount of yeast beta-glucan capable of enhancing immune responses in a subject or a host. In one embodiment, the enhanced immune responses are antitumor immune responses, which can be induced or initiated by various techniques or procedures generally known in the art. For example, antitumor immune responses can be induced by antitumor antibodies, cancer vaccines, or other compositions intended to induce immune responses against cancer.
[0008] In one embodiment, the present invention provides a yeast beta-glucan composition capable of enhancing the efficacy of antitumor antibodies and/or their derivatives. In another embodiment, the present invention provides a yeast beta-glucan composition capable of enhancing the efficacy of cancer vaccines, or the efficacy of other compositions intended to induce immune responses against cancer.
[0009] Antibodies as used herein refer to any part of immunoglobulin molecules (e.g. a monoclonal antibody) having specific cancer cell binding affinity by which they are able to exercise anti-tumor activity. Examples are antigen binding fragments or derivatives of antibodies. Furthermore, the antibody used in the present invention can be a single monoclonal antibody or a combination of antibodies . The antibodies may be directed to at least one epitope or multiple epitopes of an antigen or multiple antigens. Accordingly, this invention encompasses at least one antibody.
[0010] The cancer recognized by antibodies includes, but not limited to, neuroblastoma, melanoma, non-Hodgkin1 s
lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer colon cancer, liver cancer, stomach cancer, and other gastrointestinal cancers.
[0011] It will be recognized by one of skill in the art that the various embodiments of the invention relating to specific methods of treating tumors and cancer disease states may relate within context to the treatment of a wide number of other tumors and/or cancers not specifically mentioned herein. Thus, it should not be construed that embodiments described herein for the specific cancers mentioned do not apply to other cancers .
[0012] This invention further provides the above compositions and a pharmaceutically acceptable carrier, thereby forming pharmaceutical compositions.
[0013] This invention also provides a method for treating a subject with cancer, comprising administrating the above- described composition to the subject.
[0014] In one embodiment, the present invention provides a method for enhancing tumoricidal activities of antitumor antibody in a subject having cancer. In general, examples of cancer include, but are not limited to, neuroblastoma, melanoma, non-Hodgkin' s lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer, colon
cancer, liver cancer, stomach cancer, or other gastrointestinal cancers .
[0015] The above method comprises the steps of (a) administering to the subject antitumor antibody that binds to cancer cells in the subject; and (b) administering orally to the subject a composition comprising an effective amount of yeast glucan, wherein the orally administered glucan enhances tumoricidal activities of the antibody. In general, the antibody is a monoclonal antibody. More preferably, the antibody is capable of activating complement or activating antibody dependent cell-mediated cytotoxicity. Representative examples of antitumor antibodies include, but are not limited to, antibodies that recognize CD20, CD22, HER-2/neu, CD25, epidermal growth factor receptor, or gangliosides .
[0016] In another embodiment, the yeast glucan used in the above method has an average molecular weight of about 16,000 to about 17,000 daltons, with a range from about 6,000 to about 30,000 daltons, or from about 6,000 to about 25,000 daltons . The yeast glucan can be administered at the same or different time as the administration of the antitumor antibody. Preferably, the yeast glucan is capable of priming or inducing secretion of cytokines, chemokines or growth factors by leukocytes .
[0017] The present invention also provides a therapeutic regimen for a subject having cancer, the regimen comprising a cooperative anti-cancer effect resulting from administering to a subject in need thereof: (i) antitumor antibody that binds to cancer cells in the subject, or a cancer vaccine composition intended to induce antitumor immune responses; and (ii) an effective amount of yeast glucan which is
administered to the subject orally, wherein the orally administered glucan enhances tumoricidal activities of the antibody or the cancer vaccine composition. The yeast glucan can be administered at the same or different time as the administration of the antitumor antibody or the cancer vaccine. Examples of antitumor antibodies and yeast glucan have been described above. In general, examples of cancer vaccine include whole tumor cells, tumor cell lysates, tumor cell derived RNAs, tumor cell derived proteins, tumor cell derived peptides, tumor cell derived carbohydrates, tumor cell derived lipids, tumor cell derived DNA sequences and gene modified tumor cells, either clinically synthesized or recombinant products to serve as tumor anti-genes. These tumor cells could be derived from a patient's own tumor or tumor from an unrelated donor.
[0018] The present invention also provides uses of an effective amount of yeast glucan for preparing an anti-cancer pharmaceutical composition. The glucan is administered to a subject orally to enhance tumoricidal activities in the subject. The anti-cancer pharmaceutical composition may further comprise antitumor antibodies that bind to cancer cells in the subject, or a cancer vaccine composition intended to induce antitumor immune responses. The yeast glucan can be administered to a subject at the same or different time as the administration of the antitumor antibody or the cancer vaccine . Representative examples of antitumor antibodies, cancer vaccine, and yeast glucan have been described above .
DETAILED DESCRIPTION OP THE FIGURES
[0019] Figure 1 shows treatment of disseminating human
lymphoma in SCID mice using Rituxan and barley or yeast β- glucan. Five millions Daudi cells in 100 μl normal saline were injected intravenously (i.v.) into SCID mice. Tumors grew systemically and the mice became paralyzed when tumor cells infiltrated the spinal canal, resulting in hind-leg paralysis. The mice were sacrificed at the onset of paralysis or when the animals lost' 10% of their body weight. Therapy was initiated ten days after injection of tumor cells. Forty μg rituximab (Genentech, San Francisco, CA) was injected intravenously twice weekly for a total of eight injections and 400μg glucan was administered orally via intragastric gavage daily for 29 days. The mice were weighed weekly and observed clinically at least once daily. Mice receiving rituxan plus barley glucan or rituxan plus yeast soluble glucan have a highly significant prolonged survival (p<0.05) .
[0020] Figure 2 shows 1H NMR spectrum of a typical SBG (Soluble Beta Glucan) sample (Biotec Pharamacon ASA, Tromsø, Norway) . A SBG sample was dissolved in DMSO-de at a concentration of approximately 20 mg/ml and with a few drops of TFA-d added. The spectrum (cut-out from 2.7 to 5.5 ppm) was collected over 2 hours on a JEOL ECX 400 NMR spectrometer at 80 0C. Chemical shifts were referenced to residual proton resonance from the DMSO-d6 at 2.5 ppm, and the spectrum was baseline corrected.
[0021] Figure 3 shows viscosity profile of SBG. Profiles for a 2% solution of SBG at 20 or 30 0C at different shear rates were shown. Glycerol (87%) was used as reference solution.
[0022] Figure 4 shows beta-glucan comprising a beta-1,3- linked backbone.
[0023] Figure 5 shows beta-1, 3-glucans isolated from yeast with beta-1, 3-linked side chains anchored to the main chain through beta-1, 6 -linkage .
DETAILED DESCRIPTION OF THE INVENTION
[0024] The following terms shall be used to describe the present invention. In the absence of a specific definition set forth herein, the terms used to describe the present invention shall be given their common meaning as understood by those of ordinary skill in the art.
[0025] In the present invention the meaning of the expression "higher order conformation" defines the formation of a molecule by transformation of a collection of free atoms, which find themselves in a random spatial configuration, into a more stable non-random pattern of those same atoms. In other words, these atoms have connected themselves to each other, resulting in a new molecule, a new totality. The connection in this case is chemical, i.e. by means of chemical bonds like hydrogen bonds . Several of such molecules can in turn react with each other, resulting in other molecules, either of the same size, or possibly of a larger size. Both are new totalities again. The larger molecules are higher-order totalities.
[0026] In the present invention the expression "immunostimulating" refers to stimulating the immune system by inducing activation or increasing activity of any components of the immune system.
[0027] In the present invention the expression "immunopotentiating" refers to the activities of one substance that enhance or increase the immunostimulating effects of another substance .
[0028] The ability of beta-glucan to have immunopotentiating activity is likely the result of its ability to present multiple epitopes for interaction with receptors on the target cells, thereby clustering beta-glucan receptors and mimicking the challenge by a pathogenic organism. Such multiple interactions with specific receptors on the cell are believed to depend partly on glucan's ability to form "higher order" structures presenting multiple binding epitopes in close vicinity. Soluble beta-glucan formulations which possess durable interchain associations, as expressed by a high viscosity profile, would thus be likely candidates for expressing "immunpotentiating" abilities .
[0029] The term "cancer" refers to pathological process that results in the formation and growth of a cancerous or malignant neoplasm.
[0030] The term "effective amount" is used to describe that amount of a compound, when administered to an animal or a human, would lead to suppression or eradication of tumor growth or spread of the cancer, or other desirable immune responses.
[0031] The term "animal" is used to describe an animal, preferably a mammal, more preferably a human, to whom treatment or method according to the present invention is provided.
[0032] As used herein, the term "pharmaceutically acceptable carrier, additive or excipient" means a chemical composition with which an appropriate glucan or derivative may be combined and which, following the combination, can be used to administer the appropriate glucan to treat animals, preferable mammals, and most preferably humans.
[0033] Previously it was shown in International Applications Nos . PCT/US02/01276 and PCT/US04/23099 that oral administrated beta-1,3 and 1,4-glucans with high molecular weight and high viscosity profile isolated from barley was effective in enhancing the efficacy of i.v. administered antibodies in eradication or suppression of cancer or tumor cells. It was also shown that a composition of yeast soluble beta-glucans with beta-1, 3-linkages and specific types of side chains, thereby giving a higher order conformation with a higher viscosity profile than those used previously, surprisingly are equally active as barley-derived beta- glucans (see Figure 1) . The disclosures of PCT/US02/01276 and PCT/US04/23099 in their entireties are hereby incorporated by reference into this application.
[0034] It is generally accepted that beta-glucans of microbial origin, like yeasts, are recognised by specific pattern recognition receptors on immune cells as a result of phylogenetic adaptation for detecting possible pathogens. Beta-glucans in e.g. fungal cell walls are major structural element that secure the strength and integrity of the cell and are thus vital for the organism. Beta-1, 3-glucans are present in almost all fungal cells and they are highly conserved 'structures, the latter being a prerequisite for the so-called Pathogen Associated Molecular Patterns (PAMPs) recognised by the immune system. Immunologically active beta-glucans are likely to bind to beta-glucan receptor known
as Dectin-1 when introduced to the organism through the gastrointestinal tract.
[0035] Purified beta-1, 3-glucans having the structural elements and conformations mimicking its fungal origin as being recognised by the immune cells would thus be considered favourable with respect to achieving an immune activation, especially when administered orally. It is likely that beta- 1, 3 and 1 , 4 glucans, although not derived from a microbial organism, would interact with the immune cells based on its similarity to conserved structures on pathogenic organisms . Examples of useful beta-glucans include, but are not limited to, particulate and soluble yeast cell wall glucans as described in PCT/IB95/00265 and EP 0759089. Other beta-1, 3- glucan compositions having the ability to form interchain associations, as exemplified in having a high viscosity profile as described for the barley beta-1, 3-1, 4-glucan preparations, would also be suitable candidates. Specific preparations of e.g. lentinan, scleroglucan and schizophyllan showing durable interchain interactions are likely to be effective. Likewise, beta-1, 3-glucan formulations solublized by deriatization, like glucan phosphates, glucan sulphates, carboxymethyl-glucans, and retaining the immunopotentialting activity of the native molecule and interchain assosiation would be possible active products.
[0036] Beta-glucan formulations not presenting a pathogen- like feature could nevertheless be potent adjuvants for immunotherapy when administered directly into systemic distribution, like when given i.v. as described in Herlyn et al . (Monoclonal antibody-dependent murine macrophage-mediated cytotoxicity against human tumors is stimulated by lentinan. Jpn. J. Cancer Res. 16, 37-42 (1985)), or when given i.p. as described in U.S. Serial No'. 60/261,911.
[0037] In one embodiment, the present invention discloses a composition for achieving a synergistic therapeutic effect in an animal, preferably a mammal, most preferably a human in need thereof, comprising (i) a viscous and immunopotentiating yeast beta-glucan composition comprising a beta-1, 3-linked backbone as shown in Figure 4 and (ii) an antitumor antibody, wherein the synergistic therapeutic effect is the eradication or suppression of cancer or tumor cells . The ability of yeast beta-glucans to have immunopotentiating activity is likely due to their ability to present multiple epitopes for interaction with receptors on the target cells, thereby clustering beta-glucan receptors and mimicking the challenge by a pathogenic organism. Such multiple interactions with specific receptors on the cell are believed to depend partly on beta-glucan ' s ability to form "higher order" structures presenting multiple binding epitopes in close vicinity. Soluble beta-glucan formulations which possess durable interchain associations;, as expressed by a high viscosity profile, would also likely be candidates for expressing "immunpotentiating" abilities.
[0038] In one embodiment, the beta-glucan composition comprises yeast beta-glucans with beta-l, 3-linked main chain having a molecular weight (MW) >6000 Da, and has side chains attached thereto giving a soluble product with strong interchain assosiations . Representative examples include, but are not limited to, beta-l, 3-glucans isolated from yeast with beta-l, 3-linked side chains anchored to the main chain through beta-l, 6-linkage (see Figure 5). Suitable forms of yeast glucans include, but are not limited to, particulate, soluble, or gel form.
[0039] An example of a highly active composition of yeast beta-glucans is a mixture of soluble beta-glucan chains with molecular weight (MW) >6000 daltons that interact to give a higher order conformation which would exhibit immunostimulatory activity when administered orally to induce synergistic effect with the antibodies. In one embodiment, the mixture of soluble beta-glucans comprise linear beta-1, 3- glucan chains with MW >6000 Da, or more preferably, with MW ranging from 6000-30,000 Da, together with branched high molecular weight beta-1, 3-glucan (MW >15,000 Da) with beta- 1,3 linked side chain (s) extending from within the main chain as shown in Figure 5.
[0040] An example of the glucan as described above is SBG (Soluble Beta Glucan) produced by Biotec Pharamacon ASA
(Tromsø, Norway) . SBG, a pure natural product derived from
Bakers' yeast, is an underivatized aqueous soluble β-1, 3/1, 6- glucan characterized by NMR and chemical analysis to consist of polymers of β-l,3-linked D-glucose containing side chains of β-1, 3 and β-l,6-linked D-glucose (see Figure 2) . Preferably, the yeast glucans have an average molecular weight of about 16,000 to about 17,000 daltons, with a range from about 6,000 to about 30,000 daltons, or from about 6,000 to about 25,000 daltons
[0041] As shown in Figure 2, SBG shows a complex beta- glucan composition with high molecular weight chains having beta-1, 3-linked side chains attached to the repeating beta- 1,3-linked main chain through a beta-1, 6-linked branching point, and medium molecular weight linear beta-1, 3-glucan chains in the range of 6 - 15 kDa. SBG (Soluble Beta Glucan) presents durable interchain association as demonstrated by its high viscosity profile and gelling behavior (see Figure 3) . SBG has been shown to be a potent immunostimulating
agent for activating human leukocytes in vitro, e.g. priming and inducing the production of cytokines (see Engstad et al .
(2002) The effect of soluble beta-1, 3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int. Inuπunopharmacol . 2:1585-
1597.) , and also for modulating immune functions when given p. o. (see Breivik et al . (2005) Soluble beta-1, 3/1, 6-glucan from yeast inhibits experimental periodontal disease in
Wistar rats. J". Clinical Periodontology 32:347-3.). It is preferable for the yeast glucans of the present invention to have such functional properties of priming and inducing cytokine production by human leukocytes.
[0042] Other structures and/or structural conformations in the composition of beta-1, 3 -glucans as described above can be readily identified or isolated by a person of ordinary skill in the art following the teaching of this invention, and is expected to have similar therapeutic effect when administered through different routes other than p.o. The above is thus a guideline to achieve a highly potent product, but is not a limitation towards even more potent products. Isolated structural elements of the complex mixture as described above are expected to have improved effects over the present formulation when administered orally.
[0043] Products having the desired structural features giving a higher order conformation like SBG that facilitates the needed interaction with responding cells in the intestinal tract would be the preferred products when administered orally. Their action as immunopotentiators in synergy with anti-cancer antibodies is likely to be at least as powerful when administered parenterally, e.g. when administered i.p., s.c, i.m. or i.v. Functional dose range of the glucans can be readily determined by one of ordinary
skill in the art. For example, when administered orally the functional dose range would be in the area of 1-500 mg/kg b.w. (body weight) /day, more preferable 10-200 mg/kg b.w./day, or most preferable 20-80 mg/kg/day. In another embodiment, when administered parenterally the functional dose range would be 0.1-10 mg/kg b.w./day.
[0044] Typically, dosages of the compound of the present invention administered to an animal, preferably a human, will vary depending upon any number of factors, including but not limited to, the type of animal and type of cancer and disease state being treated, the age of the animal, the route of administration and the relative therapeutic index.
[0045] The route (s) of administration will be readily apparent to the skilled artisan and will depend upon any number of factors including the type and severity of the disease being treated, the type and age of the human patient being treated, and the like.
[0046] Formulations suitable for oral administration of the beta-glucan include, but are not limited to, an aqueous or oily suspension, an aqueous or oily solution, or an emulsion. Such formulations can be administered by any means including, but not limited to, soft gelatin capsules.
[0047] Liquid formulations of a pharmaceutical composition of the present invention which are suitable for oral administration may be prepared, packaged, and sold either in liquid form or in the form of a dry product intended for reconstitution with water or other suitable vehicle prior to use.
[0048] In general, the beta-glucan can be administered to an animal as frequently as several times daily, or it may be administered less frequently, such as once a day. The antibody treatment will for instance depend upon the type of antibody, the type of cancer, the severity of the cancer, and the condition of each patient. The beta-glucan treatment is closely interrelated with the antibody treatment regimen, and could be ahead of, concurrent with, or after the antibody administration. The frequency of the beta-glucan and antibody dose will be readily apparent to the skilled artisan and will depend upon any number of factors, such as, but not limited to, the type and severity of the disease being treated, and the type and age of the patients. Treatment with the substance of the present invention could happen at the same time or at different times. For example, the beta- glucan treatment could start a few days ahead of the i.v. antibody treatment, and then the beta-glucan is administered concurrently with the antibody. In another embodiment, beta- glucan treatment may continue for a few days after ending the antibody treatment. The antibody treatment could include a cocktail of antibodies or antibody-formulations/ modified antibodies and/or derivatives thereof .
[0049] When administered orally, glucan is taken up by macrophages and monocytes that carry these carbohydrates to the marrow and reticuloendothelial system from where they are released, in an appropriately processed form, onto myeloid cells including neutrophils and onto lymphoid cells including natural killer (NK) cells. The processed glucan binds to CR3 on these neutrophils and NK cells, and activating their antitumor cytotoxicity in the presence of tumor-specific antibodies .
[0050] The present invention provides a composition comprising an effective amount of orally administered
(l->3) , (1-^6) beta-glucan capable of enhancing the efficacy of antitumor antibodies . Glucans derived from cell walls of yeasts, such as Saccharomyces cervisiae, may be used in the above-described compositions . Preferably, glucans having β(l-3) and β(l-6) linkages, such as SBG (Soluble Beta Glucan) produced by Biotec Pharamacon ASA (Tromsø, Norway) , is used in the above-described compositions. The above mentioned pharmaceutical compositions may contain pharmaceutically acceptable carriers and other ingredients known to enhance and facilitate drug administration. The relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and condition of the subject treated.
[0051] Such a pharmaceutical composition may comprise the active ingredient alone, in a form suitable for administration to a subject, or the pharmaceutical composition may comprise the active ingredient and one or more pharmaceutically acceptable carriers, one or more additional ingredients, or some combination of these. The active ingredient may be present in the pharmaceutical composition in forms which are generally well known in the art.
[0052] The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired
single-or multi-dose unit. Controlled- or sustained-release formulations of a pharmaceutical composition of the present invention may be made using conventional technology.
[0053] In one embodiment, the above glucan composition may comprise a monoclonal antibody, or an antibody against cancer or tumor cells, which include but are not limited to anti-CEA antibody, anti-CD20 antibodies, anti-CD25 antibodies, anti- CD22 antibodies, anti-HER2 antibodies, anti-tenascin antibodies, MoAb M195, Dacluzimab, anti-TAG-72 antibodies, R24, Herceptin, Rituximab, 528, IgG, IgM, IgA, C225, Epratuzutnab, MoAb 3F8, and antibody directed at the epidermal growth factor receptor, or a ganglioside, such as GD3 or GD2. In another embodiment, the antibody is a tumor-binding antibody. Preferably, the antibody is capable of activating complement and/or activating antibody dependent cell-mediated cytotoxicity. In a further embodiment, the antibody modulates T-cell or B-cell function.
[0054] In general, the antibodies are effective against cancers which include neuroblastoma, melanoma, non-Hodgkin' s lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer, colon cancer, liver cancer, stomach cancer, or other gastrointestinal cancers.
[0055] The present invention also provides a method for treating a subject comprising administrating the above- described composition to a subject.
[0056] The present invention also provides a composition comprising an effective amount of orally administered
(1-^3) , (l->6) beta-glucan capable of enhancing the efficacy of vaccines. In one embodiment, the " vaccine is against cancer or infectious agents, such as bacteria, viruses, fungi, or parasites .
[0057] The present invention also provides a composition comprising an effective amount of orally administered (l->3) , (l->6) beta-glucan capable of enhancing host immunity. The host immunity includes, but is not limited to, antitumor immune responses.
[0058] In another embodiment, the present invention provides a composition comprising an effective amount of orally administered (l->3), (1-^6) beta-glucan capable of enhancing the action of an agent in preventing tissue rejection. In one embodiment, the tissue is transplanted tissue or transplanted organ or the host of graft-versus-host disease.
[0059] This invention also provides kits for inhibiting cancer cell growth and/or metastasis. The invention includes a kit or an administration device comprising a glucan as described herein and information material which describes administering the glucan or a composition comprising the glucan to a human. The kit or administration device may have a compartment containing the glucan or the composition of the present invention. As used herein, the "Information material" includes, but is not limited to, a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the invention for its designated use.
[0060] The invention will be better understood by reference to the Experimental Details which follow, but those
skilled in the art will readily appreciate that the specific experiments detailed are only illustrative, and are not meant to limit the invention as described herein, which is defined by the claims which follow thereafter.
EXAMPLE 1 Yeast β-Glucan Enhances Immune Responses
[0061] Whole tumor vaccines can induce tumor-specific protective immunity in preclinical tumor models . Recent clinical trials using GM-CSF-modified allogeneic or syngeneic tumor lines have yielded positive although modest clinical responses. When one reviews successful vaccines in human medicine, evidence continues to point to the importance of antibodies in both the induction as well as the maintenance of protective immunity. The persistence of cancer remission long after the completion of monoclonal antibodies strongly suggests an active immunity induced by "passive antibody therapy" . It is postulated that tumor vaccines when opsonized with specific antibodies will enhance their presentation to antigen presenting cells. In the presence of β-glucan, the efficacy of such vaccines can be further improved .
[0062] The EL4 syngeneic mouse model of lymphoma was used to study antibody response to whole tumor vaccine in the presence of β-glucan. When live EL4 tumor cells were planted subcutaneousIy or intravenously in immunocompetent C57B1/6 mice, they engrafted rapidly causing death from large tumor masses and metastases to distant organs. When EL4 tumor cells were planted subcutaneousIy or intravenously in the presence of anti-GD2 antibody 3F8, tumor cell engraftment diminished. When challenged later with EL4 cells, there was
marginal protective immunity. Since β-glucan is known to activate antigen-presenting cells, EL4 cells were administered in the presence of 3F8 as a tumor vaccine to test if β-glucan can provide adjuvant effect to induce protective immunity.
[0063] C57B1/6 mice were vaccinated subcutaneously with EL4 lymphoma (as whole tumor vaccine) in the presence of anti-GD2 antibody 3F8 plus yeast β-glucan. Mouse sera were obtained at week 2, 4, and 8 after vaccination. Serum antibodies against surface antigens on EL4 cells were assayed by flow cytometry. Antibodies against total cell antigens
(surface and cytoplasmic) were assayed by ELISA using EL4 cells bound to microtiter plates.
[0064] Results from these experiments indicate that: (1) 3F8 was necessary to prevent subcutaneous EL4 tumor engraftment; (2) 3F8 enhanced antibody response to EL4 whole tumor vaccine; (3) live EL4 tumor vaccine stimulated a significantly higher immune response compared to irradiated EL4 tumor vaccine; (4) antibody titer against EL4 tumor increased with increasing dose of glucan as an adjuvant, with an optimal dose at 2 mg; and (5) the higher the dose of glucan, the longer the mice were protected when subsequently challenged with intravenous EL4 in a tumor prevention model.
EXAMPLE 2 Phase I Study of Orally Administered Yeast β-glucan
[0065] In this phase I study, patients with refractory or recurrent metastatic stage 4 neuroblastoma were recruited. They all received anti-GD2 antibody 3F8 at 10 mg/m2/day for a total of 10 days, while being given oral yeast β-glucan. The
dose of yeast β-glucan was escalated in cohorts of 3-6 patients (10, 20, 40, 80, 100, 120 mg/kg/dose) . Eighteen patients have been registered. There were no dose limiting toxicities (DLTs) .
[0066] Three (3) patients were registered and treated at 10 mg/kg dose level. These patients have completed all four cycles of treatment. Two of these three patients showed a minor response. One patient had progressive disease.
[0067] Three (3) patients were registered and treated at the 20 mg/kg dose level. One (1) completed all four cycles with an objective response and had an additional four cycles of treatment approved by IRB. He is now completing cycle 6. One (1) patient has completed all four cycles and undergoing extent of disease evaluation. One (1) patient completed three (3) cycles of treatment and then developed human anti- mouse response <HAMA) . Extent of disease evaluation is pending.
[0068] Three (3) patients were registered and treated at the 40 mg/kg dose level. One (1) completed all four cycles of treatment. Extent of disease evaluation at the end of four cycles revealed progression of disease. One (1) patient completed one cycle of treatment. Extent of disease evaluation after one cycle revealed progressive disease. One (1) patient is now completing cycle 3.
[0069] Six (6) patients have been registered and treated at the 80 mg/kg dose level. One (1) of the patients completed all four cycles of treatment and extent of disease evaluation and had a very good partial response (VGPR) . One
(1) patient completed two cycles. Extent of disease evaluation after two cycles revealed progressive disease.
Two (2) patients completed only one cycle of treatment and had progressive disease after one cycle. One (1) patient is receiving cycle 2 of treatment. One (1) patient has completed one cycle of treatment. The latter two patients continue on protocol .
[0070] Three (3) patients were registered and treated at the 100 mg/kg dose level. There were no dose limiting toxicities. One patient (1) has progressed. One (1) patient achieved a complete remission of marrow disease . The last patient was still too early to be evaluated for response . The latter two patients continue on protocol .
REFERENCES 1. Diller, I. C, Mankowski, Z. T., and Fisher, M. E. The effect of yeast polysaccharides on mouse tumors . Cancer Res, 23: 201-208, 1963.
2. Sveinbjornsson, B., Rushfeldt, C, Seljelid, R., and Smedsrod, B. Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and beta-1, 3-D-Glucan. Hepatology, 27(5): 1241-
1248, 1998. 3. Niimoto, M., Hattori, T., Tatnada, R., Sugimachi , K., Inokuchi, K., and Ogawa, N. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful, and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Japanese Journal of Surgery, 18: 681-686, 1988.
4. Kakazato, H., Koike, A., Saji, S., Ogawa, N-, and Sakamoto, J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet, 343: 1122-1126, 1994.
5. Torisu, M., Hayashi, Y., Ishimitsu, T., Fujiπvura, T., Iwasaki, K., Katano, M., Yamato, H., Kimura, Y., Takesue, M., and Kondo, M. Significant prolongation of disease-free period gained by oral polysacharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol. Immunother. , 31: 261- 268, 1990.
6. Mitomi, T., Tsuchiya, S., Iijima, N., Aso, K., Suzuki, K., Nishiyama, K., Atnano, t., Takahashi, T., Murayama, N., and Oka, H. Randomized, controlled study on adjuvant immunochemotherapy with. PSK in curatively resected colorectal cancer. The cooperative study group of surgical adjuvant immunochemotherapy for cancer of colon and rectum (Kanagawa) . Dis Colon Rectum, 35: 123-130, 1992.
7. ogoshi, K., Satou, H., Isono, K., Mitomi, T., Endoh, M., and Sugita, M. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative study group for esophageal cancer in Japan. American Journal of Clinical Oncology, 18: 216-222, 1995.
8. Toi, M., Hattori, T., Akagi, M., Inokuchi, K., Orita, K., Sugimachi, K., Dohi , K., Nomura, Y., Monden, Y., and Hamada, Y. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization. Cancer, 70: 2475-2483, 1992.
9. Lino, Y., Yokoe, T., Maemura, M., Horiguchi, J., Takei, H., Ohwada, S., and Morishita, Y. Immunochemotherapies versus chemotheapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res., 15: 2907-2911, 1995.
10. Ohno, R., Yamada, K., Masaoka, T., Ohshima, T., Amaki, I., Hirota, Y., Horikoshi, N., Horiuchi , A., Imai, K., and Kimura, I. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother, 18: 149-154, 1984. 11. Fujimoto, S., Furue, H., Kimura, T., Kondo, T., Orita, K., Taguchi, T., Yoshida, K., and Ogawa, N. Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study. Eur J Cancer, 27: 1114-1118, 1991.
12. Furue, H., Uchino, H., Orita, K., Kimura, T., Goto, Y.,
Kondo, T., Sato, S., Takino, T., Taguchi, T., Nakao, I., and al., e. Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report) --a
randomized controlled study. Gan To Kagaku Ryoho, 12: 1272-1277, 1985.
13. Nakao, I., Uchino, H., Orita, K., Kaido, I., Kiπvura, T., Goto, Y., Kondo, T., Takino, T., Taguchi, T., Nakajima,
T., Fujimoto, S., Miya2aki, T., iVIiyoshi, A., Yachi, A., Yoshida, K. , Ogawa, N. , and Furue, H. Clinical evaluation of schizσphyllan (SPG) in advanced gastric cancer - a randomized comparative study by an envelop method. Jpn J Cancer Chemother, 10: 1146-1159, 1983.
14. Okamura, K., Suzuki, M., Chihara, T., Fujiwara, A., Fukada, T., Goto, S., Ichinohe, K., Jimi, S., Kasamatsu, T., and Kawai, N. Clinical evaluation of sizofiran conbined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy, 1: 103-107, 1989.
15. Mayell, M. Maitake extracts and their therapeutic potential. Altern Med Rev, 6: 48-60, 2001.
16. Engstad, R. and J. Raa., "Immune-stimulation improving health and performance. Feed Magazine (Kraftfutter) 7- 8,261-266 1999, Ref Type: Magazine Article
17. Nicolosi, R., S.J. Bell, B. R. Bistrian, I. Greenberg, R.A. Forse, and G. L. Blackburn 1999. "Plasma Lipid changes after supplementation with beta-glucan fiber from yeast. Am. J. Clin.Nutr 70 208-212
18. Kernodle, D.D., H.Gates, and A.B. Kaiser. 1998. Prophylactic Anti-Infective Activity of Poly- [1-6] -D- Glucopyranosyl- [1-3] -D-Glucopyranose Glucan in a Guinea Pig Model of Staphylococcal Wound Infection. Antimicrobial Agents and Chemotherapy 42: 545-549
19. Seljelid, R. 1986. "A water soluble aminated β-l,3-D- glucose derivative caused regression of solid tumors in mice. Bioscience Reports 6:845-852
20. Williams, D.L., H.A. Pretus, R.B. McNamee, E. L. Jones,
H. E. Ensley, I.W. Browder, and N.R. Di Luzio 1991. "Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology 22: 139-155
Claims
1. A method for enhancing tumoricidal activities of antitumor antibody in a subject having cancer, comprising the steps of : administering to the subject antitumor antibody that binds to cancer cells in the subject; and administering to the subject a composition comprising an effective amount of yeast glucan having an average molecular weight of about 16,000 to about
17,000 daltons and a range from about 6,000 to about 30,000 daltons, wherein the glucan enhances tumoricidal activities of the antibody.
2. The method of claim 1, wherein the antibody is a monoclonal antibody.
3. The method of claim 1 or 2 , wherein the antibody is capable of activating complement or activating antibody dependent cell-mediated cytotoxicity.
4. The method of any one of claims 1-3, wherein the antibody recognizes an antigen selected from the group consisting of CD20, CD22, HER-2/neu, CD25, epidermal growth factor receptor, and ganglioside .
5. The method of claim 4, wherein the ganglioside is GD2 or GD3.
6. The method of claim 1, wherein the cancer is neuroblastoma, melanoma, non-Hodgkin' s lymphoma, Epstein-Barr related lymphoma, Hodgkin's lymphoma, retinoblastoma, small cell lung cancer, brain tumors, leukemia, epidermoid carcinoma, prostate cancer, renal
- 2S - cell carcinoma, transitional cell carcinoma, breast cancer, ovarian cancer, lung cancer, colon cancer, liver cancer, stomach cancer, or other gastrointestinal cancers .
7. The method of claim 1, wherein the glucan is administered at the same or different time as the administration of the antibody.
8. The method of claim 1, wherein the glucan is capable of priming or inducing secretion of cytokines, chemokines or growth factors by leukocytes .
9. A therapeutic regimen for a subject having cancer, the regimen comprising a cooperative anti-cancer effect resulting from administering to a subject in need thereof : an antitumor antibody that binds to cancer cells in the subject; and an amount of yeast glucan having an average molecular weight of about 16,000 to about 17,000 daltons and a range from about 6,000 to about 30,000 daltons, wherein the amount of glucan effectively enhances tumoricidal effect of the antibody.
10. The therapeutic regimen of claim 9, wherein the glucan is administered at the same or different time as the administration of the antibody.
11. The therapeutic regimen of claim 9, wherein the antibody is capable of activating complement or activating antibody dependent cell-mediated cytotoxicity.
12. The therapeutic regimen of claim 9, wherein the antibody- is monoclonal antibody.
13. The therapeutic regimen of claim 11 or 12, wherein the antibody recognizes an antigen selected from the group consisting of CD20, CD22, HER-2/neu, CD25, epidermal growth factor receptor, and ganglioside .
14. The therapeutic regimen of claim 9, wherein the glucan is capable of priming or inducing secretion of cytokines, chemokines or growth factors by leukocytes.
15. A therapeutic regimen for a subject having cancer, the regimen comprising a cooperative anti-cancer effect resulting from administering to a subject in need thereof : a cancer vaccine composition intended to induce antitumor immune responses in the subject; and an amount of yeast glucan having an average molecular weight of about 16,000 to about 17,000 daltons and a range from about 6,000 to about 30,000 daltons, wherein the amount of glucan effectively enhances tumoricidal effect of the cancer vaccine composition.
16. The therapeutic regimen of claim 15, wherein the glucan is administered at the same or different time as the administration of the cancer vaccine composition.
17. The therapeutic regimen of claim 15, wherein the glucan is capable of priming or inducing secretion of cytokines , chemokines or growth factors by leukocytes .
18. A use of an effective amount of yeast glucan for preparing an anti-cancer pharmaceutical composition, wherein the glucan has an average molecular weight of about 16,000 to about 17,000 daltons and a range from about 6,000 to about 30,000 daltons,.
19. The use of claim 18, wherein the anti-cancer pharmaceutical composition further comprises a cancer vaccine composition intended to induce antitumor immune responses in a subject.
20. The use of claim 18, wherein the anti-cancer pharmaceutical composition further comprises antibodies that bind to cancer cells in a subject.
21. The use of claim 20, wherein the antibodies are capable of activating complement or activating antibody- dependent cell-mediated cytotoxicity.
22. The use of claim 20 or 21, wherein the antibody is monoclonal antibody.
23. The use of any one of claims 20-22, wherein the antibody recognizes an antigen selected from the group consisting of CD20, CD22, HER-2/neu, CD25, epidermal growth factor receptor, and ganglioside.
24. The use of any one of claims 20-23, wherein the antibodies is administered to a subject at the same or different time as the administration of the glucan.
25. The use of any one of claims 20-24, wherein the antibody binds to cancer cells in a subject having neuroblastoma.
26. The use of claim 19, wherein the cancer vaccine composition is administered to a subject at the same or different time as the administration of the glucan.
27. The use of any one of claims 18-26, wherein the glucan is capable of priming or inducing secretion of cytokines, chetnokines or growth factors by leukocytes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/334,763 US7906492B2 (en) | 2001-01-16 | 2006-01-17 | Therapy-enhancing glucan |
PCT/US2007/001427 WO2007084661A2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1984004A2 true EP1984004A2 (en) | 2008-10-29 |
EP1984004A4 EP1984004A4 (en) | 2010-03-03 |
Family
ID=40382391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07718218A Withdrawn EP1984004A4 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1984004A4 (en) |
JP (1) | JP2009528267A (en) |
AU (1) | AU2008207369B2 (en) |
WO (1) | WO2007084661A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
JP5153188B2 (en) * | 2007-03-30 | 2013-02-27 | 小林製薬株式会社 | Th1 / Th2 balance improver |
WO2009063221A2 (en) * | 2007-11-13 | 2009-05-22 | Biotec Pharmacon Asa | Methods of treating or preventing inflammatory diseases of the intestinal tract |
JP5242855B2 (en) * | 2010-07-29 | 2013-07-24 | 国立大学法人北海道大学 | Immune adjuvant |
WO2012105219A1 (en) * | 2011-01-31 | 2012-08-09 | オリンパス株式会社 | Antibody therapy effect-enhancing drug |
EP3373006A1 (en) | 2012-04-30 | 2018-09-12 | Biothera, Inc. | Beta-glucan immunotherapeutic methods |
EP2832360A1 (en) | 2013-07-30 | 2015-02-04 | Fresenius Kabi Deutschland GmbH | Polysaccharide for use in preventing metastasis formation and/or relapse |
JP6893594B2 (en) * | 2014-07-10 | 2021-06-23 | ハイバーセル,インク. | Β-Glucan in combination with antineoplastic agents that affect the tumor microenvironment |
US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
BR112020018761A2 (en) * | 2018-03-13 | 2020-12-29 | Hibercell, Inc. | COMBINED IMMUNOTHERAPY WITH BETA-GLUCAN AND CD40 AGONIST |
WO2019209890A1 (en) | 2018-04-24 | 2019-10-31 | Memorial Sloan Kettering Cancer Center | Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans |
WO2020061203A1 (en) * | 2018-09-21 | 2020-03-26 | Nantcell, Inc. | Methods and compositions for modulating myeloid-derived suppressor cells |
JP7048102B2 (en) | 2019-05-23 | 2022-04-05 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Application of nucleic acid polysaccharide complex with immunostimulatory activity as an antitumor drug |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817643A (en) * | 1992-08-21 | 1998-10-06 | Alpha-Beta Technology, Inc. | Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same |
WO2002058711A1 (en) * | 2001-01-16 | 2002-08-01 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
WO2005018544A2 (en) * | 2003-07-16 | 2005-03-03 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US20060009419A1 (en) * | 2002-09-04 | 2006-01-12 | Ross Gordon D | Therapy-enhancing glucan |
WO2006119395A2 (en) * | 2005-05-03 | 2006-11-09 | Biopolymer Engineering, Inc. | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340080C (en) * | 1985-03-11 | 1998-10-13 | Dorothee Herlyn | Human tumor therapy |
WO1991003495A1 (en) * | 1989-09-08 | 1991-03-21 | Alpha Beta Technology, Inc. | Method for producing soluble glucans |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5696079A (en) * | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
EP0640348A1 (en) * | 1993-07-26 | 1995-03-01 | Akzo Nobel N.V. | Oil-based and water-based adjuvant mixture |
NO300692B1 (en) * | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilized branched β-1,3-glucan and its use, as well as the use of unsolubilized branched β-1,3-glucan |
WO1997035619A1 (en) * | 1996-03-28 | 1997-10-02 | Genitrix, L.L.C. | Opsonin-enhanced cells, and methods of modulating an immune response to an antigen |
JP2004507446A (en) * | 2000-02-04 | 2004-03-11 | トーマス・ジェファーソン・ユニバーシティ | Immunotherapy of low-dose haptenized tumor cells and tumor cell extracts |
GB0211118D0 (en) * | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
-
2007
- 2007-01-17 WO PCT/US2007/001427 patent/WO2007084661A2/en active Application Filing
- 2007-01-17 JP JP2008551413A patent/JP2009528267A/en active Pending
- 2007-01-17 EP EP07718218A patent/EP1984004A4/en not_active Withdrawn
-
2008
- 2008-08-18 AU AU2008207369A patent/AU2008207369B2/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817643A (en) * | 1992-08-21 | 1998-10-06 | Alpha-Beta Technology, Inc. | Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same |
WO2002058711A1 (en) * | 2001-01-16 | 2002-08-01 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US20060009419A1 (en) * | 2002-09-04 | 2006-01-12 | Ross Gordon D | Therapy-enhancing glucan |
WO2005018544A2 (en) * | 2003-07-16 | 2005-03-03 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
WO2006119395A2 (en) * | 2005-05-03 | 2006-11-09 | Biopolymer Engineering, Inc. | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection |
Non-Patent Citations (9)
Title |
---|
CHEN ET AL: "Medicinal importance of fungal beta-(1->3), (1->6)-glucans" MYCOLOGICAL RESEARCH, ELSEVIER, GB, vol. 111, no. 6, 1 June 2007 (2007-06-01), pages 635-652, XP022163026 ISSN: 0953-7562 * |
CHEUNG N-K V ET AL: "Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies" CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 51, no. 10, 1 November 2002 (2002-11-01), pages 557-564, XP002297978 ISSN: 0340-7004 * |
HERLYN D ET AL: "Stimulation of monoclonal antibody-dependent macrophage-mediated cytotoxicity against human tumors by lentinan" INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 7, no. 3, 1 January 1985 (1985-01-01) , page 332, XP023842271 ISSN: 0192-0561 [retrieved on 1985-01-01] * |
HONG F ET AL: "Mechanism by which orally administered [beta]-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models" JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 173, no. 2, 15 July 2004 (2004-07-15) , pages 797-806, XP009125353 ISSN: 0022-1767 * |
KANEKO Y ET AL: "Activity of lentinan against cancer and AIDS" INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, BIOSCIENCE EDIPRINT INC., CAROUGE-GENEVA, CH, vol. 5, no. 4, 1 January 1989 (1989-01-01) , pages 203-213, XP009125324 ISSN: 0255-9625 * |
PELLEY R P ET AL: "Plants, polysaccharides and the treatment and prevention of neoplasia" CRITICAL REVIEWS IN ONCOGENESIS, BOCA RATON, FL, vol. 11, no. 3&4, 1 January 2000 (2000-01-01), pages 189-225, XP002963429 ISSN: 0893-9675 * |
PENNA C ET AL: "PULMONARY METASTASES NEUTRALIZATION AND TUMOR REJECTION BY IN VIVO ADMINISTRATION OF BETA GLUCAN AND BISPECIFIC ANTIBODY" INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 65, 1 January 1996 (1996-01-01), pages 377-382, XP002924638 ISSN: 0020-7136 * |
See also references of WO2007084661A2 * |
VETVICKA V ET AL: "SOLUBLE BETA-GLUCAN POLYSACCHARIDE BINDING TO THE LECTIN SITE OF NEUTROPHIL OR NATURAL KILLER CELL COMPLEMENT RECEPTOR TYPE 3 (CD11B/CD18) GENERATES A PRIMED STATE OF THE RECEPTOR CAPABLE OF MEDIATING CYTOTOXICITY OF IC3B-OPSONIZED TARGET CELLS" JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 98, no. 1, 1 July 1996 (1996-07-01), pages 50-61, XP001000371 ISSN: 0021-9738 * |
Also Published As
Publication number | Publication date |
---|---|
EP1984004A4 (en) | 2010-03-03 |
JP2009528267A (en) | 2009-08-06 |
AU2008207369B2 (en) | 2009-12-17 |
AU2008207369A1 (en) | 2008-09-11 |
WO2007084661B1 (en) | 2008-01-10 |
WO2007084661A2 (en) | 2007-07-26 |
WO2007084661A3 (en) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007084661A2 (en) | Therapy-enhancing glucan | |
US8323644B2 (en) | Therapy-enhancing glucan | |
Jin et al. | β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties | |
US7906492B2 (en) | Therapy-enhancing glucan | |
JP4903041B2 (en) | Glucan to enhance treatment | |
Akramienė et al. | Effects of ß-glucans on the immune system | |
Lang et al. | Carbohydrate conjugates in vaccine developments | |
Chen et al. | Medicinal importance of fungal β-(1→ 3),(1→ 6)-glucans | |
Cheung et al. | Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies | |
Albeituni et al. | The effects of β-glucans on dendritic cells and implications for cancer therapy | |
Baran et al. | Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice. | |
AU2006273151A1 (en) | Compositions comprising fucoidan or a fucoidan hydrolysate and an immuno-stimulating material | |
US20090053221A1 (en) | Immune response enhancing glucan | |
EP1357919B1 (en) | Therapy-enhancing glucan | |
JP2024019424A (en) | Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans | |
CN101426510A (en) | Therapy-enhancing glucan | |
Savelkoul et al. | Immunomodulatory effects of mushroom β-glucans | |
CA2637205A1 (en) | Therapy-enhancing glucan | |
Oana et al. | Natural macromolecules with protective and antitumor activity | |
WO2023042872A1 (en) | Medicament for treatment and/or prevention of cancer | |
Nam et al. | Engineered polysaccharides for controlling innate and adaptive immune responses | |
Akramiene et al. | Glucana. Efeito no sistema imune | |
MXPA06000615A (en) | Therapy-enhancing glucan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080814 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100202 |
|
17Q | First examination report despatched |
Effective date: 20100527 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20121016 |